@article{3219403,
    title = "Asthma-COPD Overlap Syndrome: Recent Insights and Unanswered Questions",
    author = "Fouka, E. and Papaioannou, A.I. and Hillas, G. and Steiropoulos, P.",
    journal = "International Journal of Person-Centered Medicine",
    year = "2022",
    volume = "12",
    number = "5",
    publisher = "MDPI",
    issn = "2043-7730, 2043-7749",
    doi = "10.3390/jpm12050708",
    abstract = "The term asthma-COPD overlap (ACO) has been used to identify a heterogeneous condition in which patients present with airflow limitation that is not completely reversible and clinical and inflammatory features of both asthma and chronic obstructive pulmonary disease (COPD). ACO diagnosis may be difficult in clinical practice, while controversy still exists regarding its definition, pathophysiology, and impact. Patients with ACO experience a greater disease burden compared to patients with asthma or COPD alone, but in contrast they show better response to inhaled corticosteroid treatment than other COPD phenotypes. Current management recommendations focus on defining specific and measurable treatable clinical traits, according to disease phenotypes and underlying biological mechanisms for every single patient. In this publication, we review the current knowledge on definition, pathophysiology, clinical characteristics, and management options of ACO. © 2022 by the authors. Licensee MDPI, Basel, Switzerland."
}